Industry Supports Shared Audits But Worries About Implementation
This article was originally published in The Gold Sheet
Lingering skepticism surfaces in Rx-360 member survey. While most support the concept of shared audits, many also worry that it will be difficult to establish the requisite uniform auditing standards.
You may also be interested in...
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
The US FDA managed to issue 94 drug GMP warning letters last year despite the pandemic, with fewer expected for 2021. Top issue areas included lack of sterility assurance, nitrosamine impurities, poor data integrity and basic GMP failures.